Tags

Type your tag names separated by a space and hit enter

Technological advances in the treatment of diabetes mellitus: better bioengineering begets benefits in glucose measurement, the artificial pancreas, and insulin delivery.
Pediatr Endocrinol Rev. 2003 Dec; 1(2):94-100.PE

Abstract

The management of type 1 diabetes is being advanced by innovations in glucose measurement, development of an artificial pancreas, and in alternate routes of insulin delivery. Emerging technologies will allow insulin to be delivered more effectively. In the future, patients with type 1 diabetes will receive insulin in optimal quantities (because of more information about blood glucose values) at optimal times (because of better integration of blood glucose values with appropriate insulin dosages) by way of optimal routes into the body (because of needle-free routes of administration) in order to achieve optimal blood glucose control. Emerging technologies for improved care of patients with type 1 diabetes include: 1. new methods for monitoring glucose, including noninvasive, minimally invasive, continuous, and alternate site measurement technologies; 2. new methods for integrating glucose values and insulin dosages, known as the artificial pancreas; and 3. new routes of insulin administration, including inhaled, oral, buccal, nasal, and transdermal drug delivery systems. These new technologies will facilitate proper treatment of type 1 diabetes and improve the lives of affected patients.

Authors+Show Affiliations

Mills-Peninsula Diabetes Research Institute, San Mateo, California 94401, USA. klonoff@itsa.ucsf.edu

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16437014

Citation

Klonoff, David C.. "Technological Advances in the Treatment of Diabetes Mellitus: Better Bioengineering Begets Benefits in Glucose Measurement, the Artificial Pancreas, and Insulin Delivery." Pediatric Endocrinology Reviews : PER, vol. 1, no. 2, 2003, pp. 94-100.
Klonoff DC. Technological advances in the treatment of diabetes mellitus: better bioengineering begets benefits in glucose measurement, the artificial pancreas, and insulin delivery. Pediatr Endocrinol Rev. 2003;1(2):94-100.
Klonoff, D. C. (2003). Technological advances in the treatment of diabetes mellitus: better bioengineering begets benefits in glucose measurement, the artificial pancreas, and insulin delivery. Pediatric Endocrinology Reviews : PER, 1(2), 94-100.
Klonoff DC. Technological Advances in the Treatment of Diabetes Mellitus: Better Bioengineering Begets Benefits in Glucose Measurement, the Artificial Pancreas, and Insulin Delivery. Pediatr Endocrinol Rev. 2003;1(2):94-100. PubMed PMID: 16437014.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Technological advances in the treatment of diabetes mellitus: better bioengineering begets benefits in glucose measurement, the artificial pancreas, and insulin delivery. A1 - Klonoff,David C, PY - 2006/1/27/pubmed PY - 2006/3/1/medline PY - 2006/1/27/entrez SP - 94 EP - 100 JF - Pediatric endocrinology reviews : PER JO - Pediatr Endocrinol Rev VL - 1 IS - 2 N2 - The management of type 1 diabetes is being advanced by innovations in glucose measurement, development of an artificial pancreas, and in alternate routes of insulin delivery. Emerging technologies will allow insulin to be delivered more effectively. In the future, patients with type 1 diabetes will receive insulin in optimal quantities (because of more information about blood glucose values) at optimal times (because of better integration of blood glucose values with appropriate insulin dosages) by way of optimal routes into the body (because of needle-free routes of administration) in order to achieve optimal blood glucose control. Emerging technologies for improved care of patients with type 1 diabetes include: 1. new methods for monitoring glucose, including noninvasive, minimally invasive, continuous, and alternate site measurement technologies; 2. new methods for integrating glucose values and insulin dosages, known as the artificial pancreas; and 3. new routes of insulin administration, including inhaled, oral, buccal, nasal, and transdermal drug delivery systems. These new technologies will facilitate proper treatment of type 1 diabetes and improve the lives of affected patients. SN - 1565-4753 UR - https://www.unboundmedicine.com/medline/citation/16437014/Technological_advances_in_the_treatment_of_diabetes_mellitus:_better_bioengineering_begets_benefits_in_glucose_measurement_the_artificial_pancreas_and_insulin_delivery_ L2 - http://www.diseaseinfosearch.org/result/2236 DB - PRIME DP - Unbound Medicine ER -